SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


National Association for Continuing Education
Speakers
Noah Kornblum, MD
Assistant Professor, Department of Medicine (Oncology)
Bone Marrow Transplant/Heme Malignancy
Montefiore Einstein Center for Cancer Care
Bronx, NY

Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd
Chief Medical Officer and Executive Vice President
CLL Society
Claremont, CA

Course Director and Moderator
Rasim A. Gucalp, MD, FACP
Professor, Department of Medicine (Oncology)
Albert Einstein College of Medicine
Montefiore Medical Center
Director, Hematology/Oncology Fellowship Program
Bronx, NY


CME Reviewer
Victor Hatcher, PhD
Associate Dean for Continuing Medical Education
Professor, Department of Biochemistry
Professor, Department of Medicine
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, NY

Title
: Clinical Advances: Individualizing Treatment for Chronic Lymphocytic Leukemia
Activity/Course #:
: NCME381
Cost:
: Free
Release/Start Date:
: Jun 15 2019
Expiration Date:
: Jun 14 2020
Topics:
: Cancer
Target Audience:
: Oncologists, Hematologists, and other clinicians that care for patients with CLL
Format:
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
Credit(s):
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.75 pharmacology hour(s)
Hardware/Software Requirements:
Program Summary
Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western countries. In 2018, there will be an estimated 20,940 new cases of CLL diagnosed and an estimated 4,510 deaths. CLL is a chronic and generally incurable disease with the average patient receiving multiple lines of therapy throughout their disease course. The treatment goal of CLL is long-term remission and the choice of treatment depends on stage, risk status, and the patient’s overall health. Achieving longterm remission typically requires combination of chemotherapy plus targeted therapies, and stem cell transplant or clinical trials for select high-risk recurrence patients.
 
Fortunately, the treatment of CLL is one of the most active areas of recent clinical research. There is not one standardized approach for treating patients with CLL. This activity will examine real-world evidence of treatment practice patterns and patient outcomes will shed significant light on how hematologists can best personalize treatment to maximize overall survival and patient quality of life.

This webcast was recorded live at the Conversations in Oncology Live Virtual Symposium 2019 and is being used with the permission of the presenters.

Learning Objectives
After completing this program participants should be able to:
  1. Use patient’s age, prognostic markers, comorbidities and patient’s preferences when individualizing CLL management
  2. Utilize new and emerging therapies as well as chemo-immunotherapy for the appropriate patients with CLL
  3. Understand the importance of degree of response to therapy, including U-MRD (undetectable Minimal Residual Disease), in managing care
  4. Recognize and manage the common complications related to the medications used to treat CLL

 How to obtain the CME Certificate

  1. Register for the course at www.naceonline.com.
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 60% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate
Sponsored and Certified By
Albert Einstein College of Medicine
Accreditation Designation Statement
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education which includes 0.75 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities.

The Conflict of Interest Disclosure Policy of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship with a commercial interest* during the past 12-month period proceeding the time that the individual is asked to assume a role controlling content of this CME activity. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present. Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. Faculty disclosures are provided below.

*The ACCME defines a commercial interest as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providing clinical service directly to patients to be commercial interests - unless the provider of the clinical service is owned, or controlled by, an ACCME-defined commercial interest.

Speakers
Dr. Kornblum has no relevant conflicts of interest with any ACCME-defined commercial interest.

Dr. Koffman has received a consulting fee from Janssen, Novartis and Verastem Oncology. He also has ownership interest in Abbvie, AstraZeneza, BeiGene, Bristol-Myers Squibb, Celgene, Gilead Sciences, Inc., Johnson & Johnson, MEI Pharma Inc, Miragen Therapeutics Inc, Portola Pharmaceuticals Inc, Sunesis Pharmaceuticals, Inc., TG Therapeutics, Inc, and Verastem Oncology

Dr Koffman has indicated that his reported relationships will not impact his ability to present an unbiased presentation.

Course Director and Moderator
Dr. Gucalp has no relevant conflicts of interest with any ACCME-defined commercial interest.

CME Reviewer
Dr. Hatcher has no relevant conflicts of interest with any ACCME-defined commercial interest.

Activity Planning Committee
Gregg Sherman, MD, has no relevant conflicts of interest with any ACCME-defined commercial interest.

Josh Kilbridge, Medical Writer, has no relevant conflicts of interest with any ACCME-defined commercial interest.

Michelle Frisch, MPH, has no relevant conflicts of interest with any ACCME-defined commercial interest.

Daniela Hiedra, BA, has no relevant conflicts of interest with any ACCME-defined commercial interest.

Sandy Bihlmeyer, MEd, has no relevant conflicts of interest with any ACCME-defined commercial interest.
Commercial Support
This educational activity is supported by an educational grant from Pharmacyclics, LLC.